Introduction To Marijuana
Marijuana has become an ubiquitous topic of conversation, which is likely fueled by the changes and proposed changes to legislation throughout the United States. Tune in as Dr. Becky Wong,… Read More
- About
- PsychU For You
- Topics
- Events
- Content
Schizophrenia
In this topic library devoted to schizophrenia you’ll find helpful resources for diagnosis and treatment—best-practice guidelines, decision-support tools, and research summaries. Each week, new content publishes, so check back often to stay up to date.
Follow Up Q&A With Dr. Rowland – The Role Of Glutamate In Mood Disorders & Schizophrenia
During this question and answer session, Dr. Laura Rowland responds to unanswered questions from the PsychU webinar, “The Role of Glutamate in Mood Disorders & Schizophrenia,” which took place on… Read MorePsychU Supporters: An Interview With Trinitas Regional Medical Center (TRMC)
We invite you to listen to our interview with James McCreath, Ph.D., LCSW, VP of Behavioral Health and Psychiatry at Trinitas Regional Medical Center (TRMC) and St. Joseph’s Health. Dr.… Read MorePsychU Supporters: An Interview With Mental Health America (MHA)
Paul Gionfriddo, President and CEO of Mental Health America (MHA), sits down with PsychU to discuss the history and purpose of MHA. Since 1909, MHA has been advocating for mental… Read MoreFollow Up Q&A With Dr. Murrough – The Role Of Glutamate In Mood Disorders & Schizophrenia
During this question and answer session, Dr. James Murrough responds to unanswered questions from the PsychU webinar, “The Role of Glutamate in Mood Disorders & Schizophrenia,” which took place on… Read MoreLong-Acting Injectable Antipsychotics & How To Give An Intramuscular Injection
In an effort to support the growing number of professionals and diverse care settings where patients are able to receive a long-acting injectable (LAI) antipsychotic medication, nurse practitioners from the… Read MoreCognitive Function & Neuroprotection In Schizophrenia
Schizophrenia has a worldwide prevalence of approximately 1%.1 Individuals living with the disease often experience neurocognitive deficits, as well as poor memory and attention, which are considered core symptoms for… Read MoreRecovery After Initial Schizophrenic Episode – Early Treatment Program (RAISE-ETP)
In this presentation, Stephen Murray, Pharm.D., MBA, Senior Medical Science Liaison for Otuska Pharmaceutical Development & Commercialization, Inc., shares insights from the Recovery After Initial Schizophrenic Episode – Early Treatment… Read MoreThe Neurobiology Of Endocannabinoids
Hear from Chloe Liu, Ph.D., a Medical Science Liaison with Otsuka Pharmaceutical Development & Commercialization, Inc., as she examines the historical research discoveries and underlying neurobiological mechanisms of the endocannabinoid… Read MoreThe Neurobiology Of Opioids
Hear from Chip Meyer, Ph.D., a Medical Science Liaison with Otsuka Pharmaceutical Development & Commercialization, Inc., as he examines the historic medical utilization and underlying neurobiological mechanisms of opioids. Explore… Read More - PsychU For You
